Edwards Lifesciences Corporation News
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
see moreEdwards Lifesciences Corporation Market News
5d
Edwards Lifesciences Q1 Beat, Guidance Lift EW
- Edwards Lifesciences reported a stronger-than-expected Q1 with $1.65B revenue, raised full-year guidance, and completed a $500M accelerated buyback—boosting sentiment even as valuation remains rich and institutional trimming surfaces.
19d
Edwards Lifesciences: CMS NCA & EU Probe Update
Key regulatory moves — EU antitrust probe closed and CMS launched its NCA for asymptomatic TAVR — plus insider buys and FDA RWE shifts that materially affect Edwards Lifesciences (EW).
30 Mar at 04:42
Edwards' Lifesciences: Recall, R&D & Insider Buys.
Edwards Lifesciences faced a voluntary recall of its Sapphire TAVR valve this week, introducing short-term sales pressure amid a company reorganization. At the same time, the firm's proxy confirms continued heavy R&D investment and strong regulatory progress, while recent insider purchases signal management confidence. Investors should weigh near-term operational risks against long-term innovation momentum.
16 Mar at 04:39
Edwards Lifesciences Gets Goldman Buy, $89 Target
Goldman Sachs reiterated a Buy rating and set an $89 target on Edwards Lifesciences (EW), citing TAVR strength and TMTT growth opportunities. Technical analysis this week also showed bullish momentum with short-term support near $83–$84 and resistance around $87–$89 — offering defined risk-reward for investors.
02 Mar at 04:39
Edwards Lifesciences: Q4 Beat, EU Win; Shares Surge
Edwards Lifesciences (EW) saw a notable stock uptick after a stronger-than-expected Q4 revenue print, lifted guidance for 2026, and resolved an EU antitrust probe by removing its anti-copycat policy. Key drivers: robust TAVR performance, rapid TMTT growth, FDA approval of SAPIEN M3, and disciplined capital returns.
23 Feb at 04:40
Edwards Lifesciences Gains After Q4 Results Rally!
Edwards Lifesciences (EW) climbed after Q4 results showed revenue slightly above estimates despite an EPS miss. Elevated trading volume, a premium valuation, and upbeat guidance underpin analyst optimism and investor interest in this S&P 500 medtech name.
16 Feb at 04:39
Edwards Lifesciences: Q4 Beat Sparks Volatility
Edwards Lifesciences reported mixed Q4 results with strong revenue growth driven by TAVR and TMTT products, an EPS miss, and a bullish 2026 outlook. The stock showed sharp post-earnings swings as investors weighed near-term investment plans against long-term growth guidance. Key drivers to monitor include TAVR reimbursement progress, execution on TMTT expansion, and trading volume signaling institutional positioning.